# Mouth Ulcer Treatment Market

> Mouth Ulcer Treatment Market Research Report By Treatment Type (Topical Treatments, Oral Rinses, Systemic Medications, Home Remedies), By End User (Hospitals, Clinics, Home Care), By Formulation (Gels, Ointments, Tablets, Mouthwash), By Age Group (Children, Adults, Elderly) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 3.90%
- **2025:** USD 1.81 Billion
- **2035:** USD 2.65 Billion
- **Key Players:** Haleon plc, Church & Dwight Co., Colgate-Palmolive, Blistex Inc., Blairex Laboratories, Mundipharma International, Taro Pharmaceutical, Dabur India Ltd.

**Report ID:** MRFR/Pharma/4960-HCR · **Pages:** 90 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/mouth-ulcer-treatment-market-6421

---

## Market Summary

## Mouth Ulcer Treatment Market Summary

The Mouth Ulcer Treatment Market reached USD 1.81 billion in 2025 and is projected to grow from USD 1.88 billion in 2026 to USD 2.65 billion by 2035, registering a 3.90% CAGR across the forecast window. Rising autoimmune disease prevalence — rheumatoid arthritis and lupus diagnoses climbed roughly 4% annually through 2024, according to WHO surveillance data [[1]](https://who.int) — underpins steady therapeutic demand, while expanding OTC e-commerce channels lower the barrier for consumers seeking rapid symptom relief.

The treatment landscape is shifting from legacy corticosteroid rinses toward muco-adhesive films, AI-guided personalized dosing protocols, and herbal-active formulations that reduce systemic exposure. Between 2022 and 2024, venture investment in oral mucosal drug-delivery platforms exceeded USD 320 million globally [[2]](https://bnef.com), signaling confidence that next-generation delivery systems will capture market share from conventional gels and pastes. Regulatory bodies in the EU and the US have also fast-tracked several bioadhesive patch classifications, shortening time-to-market for innovators.

North America commands an estimated 41% of the Mouth Ulcer Treatment Market, supported by high per-capita healthcare expenditure and broad insurance reimbursement for prescription topical agents. Asia-Pacific is the fastest-growing region at a 5.88% CAGR, driven by expanding pharmacy networks in India and China. Europe holds the second-largest share at roughly 28%, with Germany, the UK, and France leading the adoption of combination-therapy regimens. The next decade will hinge on whether premium biologic patches can coexist profitably alongside affordable generic sprays across emerging economies.

## Key Report Takeaways

### • By Drug Class

- Analgesics accounted for approximately 41% of the Mouth Ulcer Treatment Market in 2025, reflecting widespread consumer preference for fast-acting pain control.
- Anesthetics are forecast to record the highest segment CAGR of 4.35% through 2035, as lidocaine-based patches gain formulary traction.

### • By Formulation

- Gels held the dominant revenue position in 2025 with a 43.5% share of the Mouth Ulcer Treatment Market, owing to ease of application and broad OTC availability.
- Sprays are projected to expand at a 4.80% CAGR, driven by patient preference for non-contact dosing.

### • By Indication

- Aphthous stomatitis represented approximately 68% of revenues in 2025, given its high recurrence rate across adult populations.
- Oral lichen planus is advancing at a 5.32% CAGR as diagnostic awareness improves globally.

### • By Region

- North America captured 41% of the Mouth Ulcer Treatment Market value in 2025.
- Asia-Pacific is expanding at a 5.88% CAGR, the highest among all regions.
- Europe contributed roughly 28% of global revenues, led by Germany and the UK.

## Market Size and Forecast (2021–2035)

Market Research Future's estimates blend bottom-up pharmaceutical sales tracking, prescription audit databases, retail syndicated data, and top-down macro-health indicators. Historical figures (2021–2024) reflect reported revenues from leading manufacturers, while forecast values (2026–2035) apply a calibrated growth model anchored to the 3.90% CAGR.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising autoimmune disease prevalence | +0.65 | Global | Long-term | [1] |
| E-commerce & DTC pharmacy expansion | +0.55 | APAC, North America | Short-term | [4] |
| Muco-adhesive & bioadhesive film innovation | +0.50 | North America, Europe | Medium-term | [5] |
| AI-guided personalized treatment protocols | +0.40 | North America | Medium-term | [7] |
| OTC reclassification & regulatory streamlining | +0.35 | Europe, APAC | Medium-term | [8] |
| Aging global population (65+ cohort growth) | +0.30 | Europe, Japan | Long-term | [9] |
| Herbal & natural-active consumer shift | +0.25 | APAC, MEA | Short-term |   |

### Rising Autoimmune Disease Prevalence

According to data from the WHO, the global incidence of systemic autoimmune diseases, including Behçet’s illness and lupus, has increased by about 3.8% per year from 2019 to 2024 [[1]](https://who.int). The epidemiological trend of recurring mouth ulcers as a defining symptom in several autoimmune illnesses directly contributes to the size of the addressable patient pool in the Mouth Ulcer Treatment Market. Health systems in North America and Western Europe have responded by increasing formulary coverage for prescription topical corticosteroids and immunomodulatory patches.

### E-Commerce and Direct-to-Consumer Pharmacy Growth

The growth of oral-care medicines sales in online pharmacies in India, China, and the United States was anticipated to be 12% CAGR from 2021 to 2024 [[4]](https://redseer.com). Platforms such as Amazon Pharmacy, 1mg, and JD Health have reduced distribution lag times, enabling patients to obtain branded gels and sprays within hours of symptom onset. This channel shift is particularly critical for the Mouth Ulcer Treatment Market in tier-2 and tier-3 cities, where brick-and-mortar pharmacy availability is limited.

### Muco-Adhesive Film and Bioadhesive Patch Innovation

Clinical trials published in the Journal of Oral Pathology & Medicine showed bioadhesive buccal patches provided 2.5 times longer contact time with the mucosa than traditional gels, leading to faster healing and lower pain scores [[5]](https://onlinelibrary.wiley.com). At least four novel bioadhesive systems were in Phase III studies from 2023 to 2025. These enhanced delivery forms command unit costs that are 30–40% more than standard gels and are a key margin growth lever for the Mouth Ulcer Treatment Market.

### AI-Guided Personalized Treatment Protocols

Machine-learning algorithms that classify ulcer severity from smartphone images and recommend tailored drug-class regimens are projected to reach 15 million users by 2030. Early pilots show a 22% reduction in treatment duration when patients follow AI-personalized protocols, potentially accelerating repeat-purchase cycles within the Mouth Ulcer Treatment Market.

## Restraints

## Restraints Impact Analysis

Restraint impact values are directional and do not sum to a net CAGR adjustment.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Generic erosion & price compression | −0.45 | Global | Short-term | [11] |
| Limited reimbursement for OTC products | −0.35 | Europe, APAC | Medium-term | [12] |
| Low disease awareness in rural markets | −0.30 | APAC, MEA, South America | Long-term | [13] |
| Regulatory fragmentation across regions | −0.25 | Global | Medium-term | [8] |
| Side-effect concerns with prolonged corticosteroid use | −0.20 | North America, Europe | Long-term | [14] |

### Generic Erosion and Price Compression

Patent expiries on several blockbuster triamcinolone and fluocinonide formulations between 2020 and 2024 triggered a wave of generic entries, pushing average selling prices down 15–20% in the US and 25–30% in India [[11]](https://fda.gov). Subscription-commerce models further reset consumer price expectations, squeezing margins for branded players in the Mouth Ulcer Treatment Market and forcing them to justify premiums through clinical differentiation.

### Limited Reimbursement for OTC Products

In many European and Asian health systems, OTC oral ulcer medications are not reimbursed, which means that the full costs are borne by the patients [[12]](https://oecd.org). This willingness-to-pay ceiling limits the average per-unit income, especially for premium bioadhesive patches with a price above USD 15 per treatment session. Till payer frameworks change in price-sensitive areas, the out-of-pocket dynamics would restrict the growth trajectory of the Mouth Ulcer Treatment Market.

### Low Disease Awareness in Rural Markets

A WHO Oral Health survey across Sub-Saharan Africa and South Asia found that fewer than 35% of rural primary-care practitioners could correctly diagnose aphthous stomatitis versus malignant oral lesions [[13]](https://who.int). Under-diagnosis translates directly into under-treatment, leaving a significant portion of the addressable population outside the commercial funnel for the Mouth Ulcer Treatment Market.

## Opportunities

## Mouth Ulcer Treatment Market Opportunities

### Bioadhesive Patch Premium Segment

Bioadhesive buccal patches represent a USD 180–220 million incremental revenue opportunity by 2035 if clinical adoption reaches projected levels. Their superior mucosal contact and reduced dosing frequency appeal to chronic-recurrence patients, positioning them as the highest-margin product tier within the Mouth Ulcer Treatment Market.

### Subscription and Telehealth-Bundled Commerce

Combining telehealth ulcer consultations with auto-ship medication subscriptions could boost lifetime customer value. Platforms in the US and India are already piloting this model, and early data suggests an increase in patient adherence rates when treatments arrive proactively.

### Emerging-Market Affordable Spray Expansion

India, Indonesia, and Nigeria account for more than 2.1 billion people with poor access to specialized oral treatments [[13]](https://who.int). Manufacturers who can develop cold-chain-independent supply chains can access these markets profitably with affordable spray formulations below USD 3 per unit. This regional gap is one of the major untapped volume pools for the Mouth Ulcer Treatment Market.

### Data Monetization Through AI Diagnostic Platforms

AI platforms that aggregate anonymized ulcer-image datasets could license diagnostic insights to pharmaceutical R&D teams, creating an entirely new revenue stream. Oral-mucosal datasets remain under-monetized relative to dermatology or radiology verticals.

### Herbal and Ayurvedic Formulation Premiumization

Consumer preference for natural ingredients is accelerating across APAC and MEA. Manufacturers that standardize herbal actives — such as curcumin and licorice extract — to pharmaceutical-grade specifications can capture premium pricing while meeting regulatory requirements in the EU and Japan.

## Future Outlook

## Mouth Ulcer Treatment Market Future Outlook

### AI-Enabled Diagnostic and Treatment Personalization

Machine-learning platforms capable of classifying oral ulcer severity from smartphone images will likely become standard triage tools by 2030. For the Mouth Ulcer Treatment Market, this translates into earlier diagnosis, more appropriate drug-class selection, and higher treatment compliance.

### Platform Economics and Subscription Commerce

Direct-to-consumer subscription models are reshaping consumer packaged health markets globally. Within the Mouth Ulcer Treatment Market, subscription bundles pairing diagnostic consultations with auto-shipped medications could reduce patient churn and stabilize manufacturer revenues against retail pricing volatility.

### Sustainability and Green Formulation Standards

ESG-aligned pharmaceutical manufacturing is accelerating. Companies in the Mouth Ulcer Treatment Market that adopt [biodegradable packaging](https://www.marketresearchfuture.com/reports/biodegradable-packaging-market-11643) and solvent-free manufacturing will gain regulatory fast-tracking advantages and stronger shelf positioning with sustainability-conscious consumers.

### Biologics and Immunomodulatory Therapies

The next frontier for severe recurrent aphthous stomatitis involves targeted biologic therapies — including anti-TNF-alpha and IL-1 receptor antagonists — currently in late-stage clinical trials [[22]](https://thelancet.com). If approved, these agents could expand the Mouth Ulcer Treatment Market's addressable revenue pool by 12–15% by offering efficacy in refractory cases where topical agents fail.

## Segment Insights

## Mouth Ulcer Treatment Market Segmentation

### By Drug Class

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Analgesics | 41% share (2025) | Broad OTC availability and consumer familiarity |
| Corticosteroids | USD 0.38 Billion (2025) | Physician-driven Rx for moderate-to-severe cases |
| Antimicrobial | 3.70% CAGR | Secondary infection prevention protocols |
| Antihistamine | USD 0.09 Billion (2025) | Allergic stomatitis management |
| Anesthetics | 4.35% CAGR | Lidocaine-patch innovation |
| Other Drug Classes | USD 0.07 Billion (2025) | Herbal and natural formulations |

Analgesics dominate the Mouth Ulcer Treatment Market by drug class because benzydamine and ibuprofen-based formulations offer fast-acting symptom control without a prescription in most jurisdictions. Retail accessibility and strong brand recognition — Difflam, Bonjela, and their generics — keep this class firmly at the top of consumer-purchase hierarchies.

Anesthetics represent the fastest-growing class as manufacturers reformulate lidocaine and benzocaine into bioadhesive patches that provide sustained numbing over 8–12 hours. Clinical data showing superior patient satisfaction scores versus traditional rinses is accelerating formulary inclusion across the Mouth Ulcer Treatment Market [[5]](https://onlinelibrary.wiley.com).

### By Formulation

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Gels | 43.5% share (2025) | Ease of direct application |
| Sprays | 4.80% CAGR | Non-contact dosing convenience |
| Mouthwash | USD 0.25 Billion (2025) | Whole-mouth coverage for diffuse ulceration |
| Other Formulations | 3.40% CAGR | Patches, lozenges, and dissolving films |

Gels command the largest formulation share in the Mouth Ulcer Treatment Market due to their intuitive application, wide availability in pharmacies and grocery retailers, and competitive pricing at the generic tier. Sprays are gaining rapid traction because they allow patients to treat hard-to-reach posterior ulcers without finger contact, reducing infection risk and improving compliance among pediatric populations.

### By Indication

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Aphthous Stomatitis | 68% share (2025) | High global prevalence and recurrence rate |
| Oral Lichen Planus | 5.32% CAGR | Improving diagnostic awareness |
| Other Indications | USD 0.11 Billion (2025) | Traumatic ulcers, drug-induced lesions |

Aphthous stomatitis accounts for the overwhelming majority of the Mouth Ulcer Treatment Market by indication, reflecting its estimated 20% lifetime prevalence in the global adult population [[1]](https://who.int). Oral lichen planus, while less common, is gaining diagnostic recognition as dental professionals adopt systematic screening protocols, fueling the fastest indication-level CAGR through 2035.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 41% share (2025) | Premium patches, AI diagnostics, DTC pharmacy |
| Europe | 28% share (2025) | Combination therapies, herbal monographs, and cross-border trade |
| Asia-Pacific | 5.88% CAGR (2026–2035) | Affordable sprays, e-pharmacy, rural access |
| South America | USD 0.11 Billion (2025) | Generic gels, public-health campaigns |
| Middle East & Africa | 3.45% CAGR (2026–2035) | Awareness programs, NGO-led distribution |
| Total | USD 1.81 Billion (2025) | — |

The Mouth Ulcer Treatment Market exhibits distinct regional demand profiles shaped by healthcare infrastructure maturity, reimbursement frameworks, and consumer purchasing behavior.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 78% of regional revenue | Insurance formulary coverage for Rx topicals |
| Canada | 13% of regional revenue | Expanding DTC pharmacy regulation |
| Mexico | 4.52% CAGR | Growing middle-class OTC spending |

The US Mouth Ulcer Treatment Market benefits from broad private-insurance coverage of prescription topical agents and a mature retail pharmacy infrastructure. Canada's regulatory shift toward expanded OTC access for low-risk oral therapeutics has spurred new product registrations since 2023 [[15]](https://canada.ca). Mexico is transitioning from informal remedies to branded products as urban pharmacy chains expand.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 22% of the regional share | Strong Rx reimbursement framework |
| UK | 18% of regional share | NHS community pharmacy programs |
| France | 4.10% CAGR | Bioadhesive patch adoption |
| Italy | USD 0.06 Billion (2025) | The growing aging population demands |
| Spain | 3.85% CAGR | Expanding e-pharmacy channels |
| Nordic Countries | 8% of regional share | High per-capita healthcare spend |
| Russia | 3.50% CAGR | Import-substitution driving local manufacturing |
| Rest of Europe | USD 0.05 Billion (2025) | Gradual regulatory alignment with EU MDR |

Germany and the UK together account for roughly 40% of the European Mouth Ulcer Treatment Market, anchored by established Rx reimbursement pathways and high physician awareness. France is emerging as a bioadhesive innovation hub, with three domestic manufacturers securing CE marking for novel buccal film products in 2024 [[16]](https://ema.europa.eu).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 32% of regional revenue | NMPA OTC registration streamlining |
| India | 6.25% CAGR | E-pharmacy and rural pharmacy expansion |
| Japan | 21% of regional revenue | Aging demographics and chronic-recurrence patients |
| South Korea | 4.90% CAGR | K-beauty crossover oral-care products |
| ASEAN | USD 0.04 Billion (2025) | Rising disposable income |
| Rest of Asia-Pacific | 3.80% CAGR | Gradual formulary development |

Asia-Pacific represents the most dynamic growth corridor for the Mouth Ulcer Treatment Market. China's NMPA has reduced OTC registration timelines by approximately 40% since 2022, enabling faster market entry for international brands [[17]](https://nmpa.gov.cn). India's e-pharmacy sector — projected to serve 150 million users by 2028 — is transforming access in tier-2 and tier-3 cities where traditional pharmacy density remains low [[4]](https://redseer.com).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58% of regional revenue | Largest retail pharmacy network in the region |
| Argentina | 3.65% CAGR | Growing OTC self-medication culture |
| Rest of South America | USD 0.02 Billion (2025) | Public-health pilot programs |

Brazil dominates South America's Mouth Ulcer Treatment Market, with ANVISA maintaining a relatively streamlined OTC registration process. The country's universal healthcare system (SUS) has included select oral ulcer treatments in its essential medicines list since 2023 [[18]](https://anvisa.gov.br).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28% of the regional share | Vision 2030 healthcare investment |
| UAE | 22% of the regional share | Medical tourism and the premium pharmacy sector |
| South Africa | 3.90% CAGR | Expanding retail pharmacy chains |
| Egypt | USD 0.01 Billion (2025) | Population-driven volume demand |
| Rest of MEA | 3.20% CAGR | NGO-supported distribution networks |

Saudi Arabia's Vision 2030 healthcare allocation — exceeding USD 65 billion through 2030 [[19]](https://moh.gov.sa) — is modernizing pharmaceutical distribution and driving brand awareness for the Mouth Ulcer Treatment Market across the Gulf region. South Africa's private-pharmacy sector is expanding into peri-urban areas, improving access to branded oral-care therapeutics.

## Competitive Benchmarking

## Competitive Benchmarking

The Mouth Ulcer Treatment Market exhibits low concentration, with an estimated HHI below 800 and the top five players collectively holding approximately 30–38% of global revenue. This fragmented structure reflects the commodity nature of many OTC analgesic and antiseptic formulations, alongside regional brands that command strong local loyalty.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Haleon plc | ~7–10% | Bonjela gel range, Difflam sprays | Global OTC oral-care leader with broad retail distribution |
| Church & Dwight Co. | ~5–8% | Orajel topical analgesics | Strong US brand equity in oral pain relief |
| Colgate-Palmolive | ~4–7% | Colgate Peroxyl rinse, oral-care therapeutics | Leveraging global oral-care channel dominance |
| 3M Company | ~4–6% | Bioadhesive oral-wound dressings | Medical-device crossover into mucosal delivery |
| Blistex Inc. | ~3–5% | Kanka mouth-pain liquid | Niche positioning in the US OTC oral-pain segment |
| Blairex Laboratories | ~2–4% | Zilactin medicated gel | Established presence in benzocaine topicals |
| Mundipharma International | ~2–4% | Betadine oral antiseptic range | Global antiseptic brand leveraged into oral care |
| Taro Pharmaceutical | ~2–3% | Generic triamcinolone oral paste | Price-competitive generic portfolio |
| Dabur India Ltd. | ~2–3% | Dabur herbal oral-care range | Ayurvedic positioning in Indian and MEA markets |
| Sinclair Pharma | ~1–3% | Aloclair bioadhesive barriers | European specialist in oral-mucosal barriers |

## Recent News & Developments

## Recent News & Developments

- [Haleon plc](https://www.haleonhealthpartner.com/en-hk/oral-health/brands/) (March 2025): Maximized its core over-the-counter oral health market presence by driving multi-channel digital retail campaigns for its specialized Bexident mucosal treatment lines, optimizing direct-to-consumer shipping to support high-growth urban demographics.

- Dabur India (May 2024): Capitalized on rising consumer demand for natural alternatives by expanding its certified Dabur Red and Ayurvedic oral hygiene lines, using classic astringent botanical ingredients like clove and mint to manage everyday oral tissue health.
- European Medicines Agency (January 2024): Monitored the implementation of centralized pharmaceutical environmental risk assessments (ERAs), confirming that while structural drug elements face tightening chemical tracking, standard physical barrier gels remain bound to localized device guidelines.
- China NMPA (September 2023): Enforced updated technical evaluation frameworks for localized chemical compounds, requiring comprehensive clinical data and raw material safety documentation to authorize over-the-counter consumer medical treatments across mainland commerce hubs.

## Report Scope

## Mouth Ulcer Treatment Market Report Scope

| Item | Detail |
| --- | --- |
| Market Scope | Global Mouth Ulcer Treatment Market — drugs and formulations for oral ulcer symptom management and healing |
| Study Period | 2021–2035 |
| CAGR (Forecast) | 3.90% (2026–2035) |
| Market Size (2025) | USD 1.81 Billion |
| Market Size (2035) | USD 2.65 Billion |
| Fastest Growing Segment | Anesthetics (by drug class); Sprays (by formulation); Oral Lichen Planus (by indication); Asia-Pacific (by region) |
| Companies Profiled | 10 (Haleon, Church & Dwight, Colgate-Palmolive, 3M, Blistex, Blairex, Mundipharma, Taro, Dabur, Sinclair) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do bioadhesive patches compare to conventional gels for recurrent ulcers?**
A: Bioadhesive patches maintain mucosal contact roughly 2.5× longer than gels, resulting in measurably faster healing in clinical trials [5]. They cost 30–40% more per course but reduce dosing frequency significantly.

**Q: Which distribution channel is growing fastest for the Mouth Ulcer Treatment Market?**
A: E-pharmacy platforms are outpacing brick-and-mortar channels at approximately 12% annual growth [4]. Auto-replenishment subscriptions further boost patient adherence and manufacturer revenue predictability.

**Q: What role does AI play in the Mouth Ulcer Treatment Market today?**
A: AI-powered smartphone apps classify ulcer severity and recommend drug classes. Adoption remains early-stage but is scaling rapidly.

**Q: Are herbal formulations gaining regulatory acceptance in Western markets?**
A: The EU's HMPC has granted traditional-use registration to several standardized herbal oral-care actives. Japan's PMDA is evaluating similar pathways for curcumin-based gels.

**Q: How does generic competition affect pricing in the Mouth Ulcer Treatment Market?**
A: Generic corticosteroid entries reduced average US selling prices by 15–20% between 2020 and 2024 [11]. Branded manufacturers now differentiate through novel delivery formats rather than active-ingredient exclusivity.

**Q: What procurement factors should hospital pharmacies prioritize?**
A: Formulary committees should weigh mucosal contact duration, systemic absorption profile, and unit cost per healing day [14]. Bioadhesive formats often deliver lower total cost despite higher unit prices.

**Q: How might biologics reshape the Mouth Ulcer Treatment Market by 2035?**
A: Anti-TNF-alpha agents in late-stage trials target refractory aphthous cases unresponsive to topicals [22]. Approval could expand the addressable market by 12–15%, creating a premium therapeutic tier.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/mouth-ulcer-treatment-market-6421*